Tardive Dyskinesia Treatment | AUSTEDO XR® (deutetrabenazine)
Reduce involuntary movements with AUSTEDO XR® (deutetrabenazine) tablets treatment for TD. See safety info and boxed warning.
Tardive Dyskinesia (TD) | AUSTEDO XR® (deutetrabenazine) …
AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and …
Austedo (deutetrabenazine): Uses, Side Effects, Dosage Guide
Aug 20, 2025 · Austedo's drug class is a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor). Austedo tablets are taken twice daily, and the Austedo XR (extended-release) tablets are taken once …
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR ...
4 days ago · The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets or AUSTEDO XR (deutetrabenazine) extended-release tablets for tardive dyskinesia (TD) led to …
Deutetrabenazine Tablets Improve Tardive Dyskinesia Symptoms
Oct 22, 2025 · Teva Pharmaceuticals announced new data from the ongoing, real-world IMPACT-TD Registry, which demonstrates that treatment with deutetrabenazine tablets or deutetrabenazine …
Austedo Phase 4 Data Shows Reduction in Tardive Dyskinesia Severity
Nov 12, 2025 · Austedo standard and XR tablets are currently indicated for adults for the treatment of chorea in Huntington disease and tardive dyskinesia. Austedo is the first VMAT2 inhibitor approved …
What is the FDA-Approved Treatment for Tardive Dyskinesia?
Nov 26, 2025 · Learn about the FDA-approved treatment for tardive dyskinesia, specifically the VMAT2 inhibitors valbenazine (Ingrezza) and deutetrabenazine (Austedo).
Teva Pharmaceuticals Reports Positive Real-World Data on AUSTEDO …
Nov 7, 2025 · Teva Pharmaceuticals presented new findings from the IMPACT-TD Registry indicating that treatment with AUSTEDO and AUSTEDO XR significantly improved the lives of adults with …
How to Tell If a Tardive Dyskinesia Treatment Plan Is Working
6 days ago · Treating tardive dyskinesia The most common option for treating TD is a vesicular monoamine transporter (VMAT2) inhibitor. The two FDA-approved options are valbenazine …
FDA Approves One Pill, Once-Daily Tablets of Deutetrabenazine for ...
May 30, 2024 · The FDA has approved a new one-pill, once-daily tablet administration option for deutetrabenazine (Austedo XR; Teva Pharmaceuticals), a medication for tardive dyskinesia and …